Preferred Label : Garsorasib;
NCIt synonyms : KRAS G12C Inhibitor D-1553; 4-((2S,5R)-4-Acryloyl-2,5-dimethylpiperazin-1-yl)-7-(2-amino-6-fluorophenyl)-1-(4,6-dicyclopropylpyrimidin-5-yl)-6-fluoropyrido(2,3-d)pyrimidin-2(1H)-one; Pyrido(2,3-d)pyrimidin-2(1H)-one, 7-(2-amino-6-fluorophenyl)-1-(4,6-dicyclopropyl-5-pyrimidinyl)-4-((2S,5R)-2,5-dimethyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-6-fluoro-;
NCIt definition : An orally available inhibitor of the oncogenic KRAS substitution mutation, G12C, with
potential antineoplastic activity. Upon oral administration, garsorasib selectively
targets the KRAS G12C mutant and inhibits KRAS G12C mutant-dependent signaling. KRAS,
a member of the RAS family of oncogenes, serves an important role in cell signaling,
division and differentiation. Mutations of KRAS may induce constitutive signal transduction
leading to tumor cell growth, proliferation, invasion, and metastasis.;
UNII : P491NE9G6Z;
CAS number : 2559761-14-5; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2559761-14-5
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Molecule name : D-1553; D 1553;
NCI Metathesaurus CUI : CL1648078;
Origin ID : C178562;
UMLS CUI : C5706581;
Semantic type(s)
- concept_is_in_subset
- has_target
